CTSO

Cytosorbents Corporation [CTSO] Stock Forecast

Q: What is Cytosorbents Corporation stock symbol ?

Cytosorbents Corporation is a US stock, located in Monmouth junction of New jersey and trading under the symbol CTSO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

Stock Summary

Earnings have grown 5.27% per last year.

EPS has been decreasing for the past 3 quarters (Quarter statements)

Profit margins (-3.86%) are lower than the previous year (-0.57%)

CTSO has less than 1 year of cash runway

Top Correlated Resources

CTSO

Top 10 Correlated ETFs

CTSO

Top 10 Correlated Stocks

CTSO

In the News

06:20 29 Nov 2022 CTSO

CytoSorbents Corporation (CTSO) Q3 2022 Earnings Call Transcript

CytoSorbents Corporation (NASDAQ:CTSO ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Michelle Almonte - Executive Assistant to CEO Phillip Chan - Chief Executive Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - EVP of Sales and Marketing and Managing Director of CytoSorbents Europe GmbH Efthymios Deliargyris - Chief Medical Officer Vincent Capponi - Chief Operating Officer and President Christopher Cramer - VP of Business Development Conference Call Participants Zachary Weiner - Jefferies Sean Lee - H.C. Wainwright Operator Good day, and welcome to the CytoSorbents Corporation Third Quarter 2022 Earnings Conference Call.

09:49 29 Nov 2022 CTSO

CytoSorbents (CTSO) Reports Q3 Loss, Misses Revenue Estimates

CytoSorbents (CTSO) delivered earnings and revenue surprises of -75% and 9.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

07:00 29 Nov 2022 CTSO

CytoSorbents to Report Third Quarter 2022 Operating and Financial Results

PRINCETON, N.J. , Oct. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022.

11:03 29 Nov 2022 CTSO

Cytosorbents Corporation's (CTSO) CEO Phillip Chan on Q2 2022 Results - Earnings Call Transcript

Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Amy Vogel – Investor Relations Phillip Chan – Chief Executive Officer Kathleen Bloch – Chief Financial Officer Christian Steiner – Executive Vice President-Sales and Marketing and Managing Director-Cytosorbents Europe GmbH Christopher Cramer – Vice President-Business Development Efthymios Deliargyris – Chief Medical Officer Vincent Capponi – Chief Operating Officer and President Mike Gibson – Principal Co-Investigator-STAR-T Conference Call Participants Zach Weiner – Jefferies Brian Kennedy – Cowen Sean Lee – H.C. Wainwright Operator Good afternoon, and welcome to Cytosorbents Second Quarter 2022 Financial and Operating Results Conference Call.

07:00 29 Nov 2022 CTSO

CytoSorbents to Report Second Quarter 2022 Operating and Financial Results

PRINCETON, N.J. , July 25, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2022 operating and financial results after the market close on August 2 nd, 2022.

07:54 29 Nov 2022 CTSO

3 Stocks Under $3 Insiders Are Aggressively Buying

The Nasdaq Composite dropped by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades.

02:54 29 Nov 2022 CTSO

10 Top Penny Stocks To Buy In June According To These Insiders Part 1

Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

12:11 29 Nov 2022 CTSO

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2022 Results - Earnings Call Transcript

Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Terri Anne Powers - Vice President, Investor Relations & Corporate Communications Phillip Chan - Chief Executive Officer Vincent Capponi - President & Chief Operating Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales & Marketing and Managing Director of Cytosorbents Europe Christopher Cramer - Vice President, Business Development Efthymios Deliargyris - Chief Medical Officer Conference Call Participants Frank Pinal - Jefferies Justin Walsh - B. Riley Securities Zach Weiner - Jefferies Priya Sachdeva - SVB Operator Good afternoon and welcome to the Cytosorbents Corp.'s First Quarter 2022 Earnings Conference Call.

09:50 29 Nov 2022 CTSO

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q4 2021 Results - Earnings Call Transcript

07:00 29 Nov 2022 CTSO

CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

MONMOUTH JUNCTION, N.J., Feb. 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2021 operating and financial results after the market close on March 8, 2022.

Financial details

Company Rating

Neutral

Market Cap

65.89M

Income

-41.35M

Revenue

10.72M

Book val./share

0.9

Cash/share

0.52

Dividend

Dividend %

Employees

221

Optionable

Shortable

Yes

Earnings

03 Nov 2022

P/E

-2.22

Forward P/E

PEG

-0.06

P/S

6.14

P/B

1.68

P/C

2.63

P/FCF

-2.26

Quick Ratio

2.72

Current Ratio

3.2

Debt / Equity

0.33

LT Debt / Equity

0.33

EPS (TTM)

-0.95

EPS next Y

EPS next Q

EPS this Y

185%

EPS next Y

EPS next 5Y

EPS last 5Y

12.24%

Revenue last 5Y

23.29%

Revenue Q/Q

-11.84%

EPS Q/Q

12%

SMA20

-14.29%

SMA50

-20.88%

SMA100

-33.94%

Inst Own

34.09%

Inst Trans

-3.14%

ROA

-66%

ROE

-81%

ROC

-0.67%

Gross Margin

-25%

Oper. Margin

-324%

Profit Margin

-386%

Payout

Shs Outstand

43.58M

Shs Float

37.27M

Target Price

52W Range

1.18-5.4

52W High

-72.6%

52W Low

+37%

RSI

41.4

Rel Volume

0.46

Avg Volume

170.88K

Volume

79.01K

Perf Week

-4.86%

Perf Month

-13.84%

Perf Quarter

-46.48%

Perf Half Y

-29.02%

Beta

0.700398

Volatility

0.05%, 0.17%

Prev Close

-9.27%

Price

1.37

Change

-7.43%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	0.55	0.73	0.77	1.06	1.11
Net income per share	-0.31	-0.56	-0.6	-0.2	-0.63
Operating cash flow per share	-0.23	-0.35	-0.52	-0.14	0
Free cash flow per share	-0.29	-0.4	-0.57	-0.19	0
Cash per share	0.63	0.73	0.38	1.84	1.34
Book value per share	0.37	0.55	0.11	2.04	1.61
Tangible book value per share	0.31	0.47	0	1.93	1.61
Share holders equity per share	0.37	0.55	0.11	2.04	1.61
Interest debt per share	0.36	0.37	0.51	0.04	0.02
Market cap	209.87M	227.01M	159.99M	407.21M	135.48M
Enterprise value	202.54M	214.59M	163.23M	336.24M	83.91M
P/E ratio	-24.8	-13.19	-8.3	-51.96	-5.52
Price to sales ratio	13.85	10.09	6.41	9.93	3.14
POCF ratio	-32.48	-20.94	-9.55	-72.54	0
PFCF ratio	-25.79	-18.37	-8.75	-55.86	0
P/B Ratio	20.45	13.41	46.81	5.14	2.16
PTB ratio	20.45	13.41	46.81	5.14	2.16
EV to sales	13.37	9.54	6.54	8.2	1.94
Enterprise value over EBITDA	-22.71	-13.43	-8.71	-47.34	-3.32
EV to operating cash flow	-31.35	-19.8	-9.74	-59.9	0
EV to free cash flow	-24.89	-17.36	-8.93	-46.13	0
Earnings yield	-0.04	-0.08	-0.12	-0.02	-0.18
Free cash flow yield	-0.04	-0.05	-0.11	-0.02	0
Debt to equity	0.58	0.55	3.92	0	0
Debt to assets	0.57	0.48	0.88	0.12	0.3
Net debt to EBITDA	0.82	0.78	-0.17	9.99	2.04
Current ratio	2.64	4.32	2.1	8.12	4.7
Interest coverage	0	-10.67	-18.36	-8.63	-812.11
Income quality	0.76	0.63	0.87	0.72	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.02	1.02	0.98	0.77	0
Research and developement to revenue	0.27	0.34	0.48	0.21	0.38
Intangibles to total assets	0.08	0.08	0.12	0.05	0
Capex to operating cash flow	0.26	0.14	0.09	0.3	0
Capex to revenue	-0.11	-0.07	-0.06	-0.04	0
Capex to depreciation	-7.69	-3.89	-2.61	-2.54	0
Stock based compensation to revenue	0.22	0.2	0.11	0.11	0
Graham number	1.6	2.64	1.19	3.04	4.79
ROIC	-0.61	-0.59	-1.09	-0.13	-0.3
Return on tangible assets	-0.38	-0.57	-0.8	-0.09	-0.27
Graham Net	0.2	0.32	-0.23	1.7	0.8
Working capital	12.89M	21.73M	10.97M	72.3M	50.61M
Tangible asset value	8.42M	14.31M	56.63K	74.99M	0
Net current asset value	6.9M	12.45M	-3.06M	71.72M	37.36M
Invested capital	0.97	0.59	4.53	0.01	0.01
Average receivables	3.68M	4.55M	4.81M	5.16M	4.84M
Average payables	2.02M	2.22M	2.57M	2.47M	2.64M
Average inventory	1.73M	1.75M	2.39M	2.67M	3.72M
Days sales outstanding	53.14	63.96	65.35	45.92	38.25
Days payables outstanding	103.63	95.79	132.26	81.46	92.68
Days of inventory on hand	52.63	40.6	104.78	88.3	157.47
Receivables turnover	6.87	5.71	5.59	7.95	9.54
Payables turnover	3.52	3.81	2.76	4.48	3.94
Inventory turnover	6.94	8.99	3.48	4.13	2.32
ROE	-0.82	-1.02	-5.64	-0.1	-0.39
Capex per share	-0.06	-0.05	-0.05	-0.04	0

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-09-30	2021-12-31	2022-03-31	2022-06-30	2022-09-30
Revenue per share	0.22	-0.25	0.18	0.17	0.15
Net income per share	-0.15	-0.21	-0.21	-0.25	-0.28
Operating cash flow per share	-0.1	0	-0.19	-0.18	-0.15
Free cash flow per share	-0.12	0	-0.21	-0.29	-0.17
Cash per share	1.41	1.2	0.99	0.69	0.52
Book value per share	1.63	1.44	1.27	1.09	0.9
Tangible book value per share	1.63	1.44	1.27	1.09	0.9
Share holders equity per share	1.63	1.44	1.27	1.09	0.9
Interest debt per share	0.31	0.01	0.31	0.31	0.31
Market cap	352.38M	182.17M	138.73M	95.4M	59.31M
Enterprise value	304.99M	130.6M	109.36M	78.74M	50.14M
P/E ratio	-13.75	-4.89	-3.87	-2.19	-1.22
Price to sales ratio	36.1	-16.56	17.51	13.01	9.18
POCF ratio	-85.25	0	-17.09	-11.87	-8.81
PFCF ratio	-68.41	0	-15.47	-7.5	-7.96
P/B Ratio	4.99	2.91	2.5	2.01	1.52
PTB ratio	4.99	2.91	2.5	2.01	1.52
EV to sales	31.25	-11.87	13.8	10.74	7.76
Enterprise value over EBITDA	-49.44	-13.03	-12.6	-7.46	-9.1
EV to operating cash flow	-73.78	0	-13.47	-9.79	-7.44
EV to free cash flow	-59.21	0	-12.2	-6.19	-6.73
Earnings yield	-0.02	-0.05	-0.06	-0.11	-0.21
Free cash flow yield	-0.01	0	-0.06	-0.13	-0.13
Debt to equity	0.19	0	0.24	0.28	0.33
Debt to assets	0.26	0.3	0.33	0.33	0.37
Net debt to EBITDA	7.68	5.14	3.38	1.58	1.66
Current ratio	6.57	4.7	3.81	3.95	3.2
Interest coverage	0	-534.69	-970.62	-348.6	-192.49
Income quality	0.65	0	0.91	0.74	0.55
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.86	0	1.26	1.24	1.45
Research and developement to revenue	0.44	-0.56	0.54	0.57	0.51
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.25	0	0.1	0.58	0.11
Capex to revenue	-0.1	0	-0.11	-0.64	-0.11
Capex to depreciation	-4.29	0	-3.01	-15.97	-2.58
Stock based compensation to revenue	0.14	0	0.12	0.05	0.21
Graham number	2.32	2.63	2.43	2.48	2.38
ROIC	-0.06	-0.13	-0.11	-0.14	-0.17
Return on tangible assets	-0.07	-0.1	-0.11	-0.15	-0.2
Graham Net	0.99	0.71	0.49	0.3	0.11
Working capital	61.68M	50.61M	41.18M	31.09M	22.26M
Tangible asset value	0	0	0	0	0
Net current asset value	48.3M	37.36M	28.01M	18M	9.25M
Invested capital	0.19	0.01	0.25	0.28	0.34
Average receivables	5.21M	4.85M	4.87M	5.17M	5.07M
Average payables	2.74M	2.47M	3.48M	2.13M	2.24M
Average inventory	4.75M	4.87M	5.21M	4.98M	4.26M
Days sales outstanding	48.33	-37	51.98	63.48	69.09
Days payables outstanding	122.7	80.85	190.69	53.97	47.02
Days of inventory on hand	165.44	137.36	215.18	126.24	70.93
Receivables turnover	1.86	-2.43	1.73	1.42	1.3
Payables turnover	0.73	1.11	0.47	1.67	1.91
Inventory turnover	0.54	0.66	0.42	0.71	1.27
ROE	-0.09	-0.15	-0.16	-0.23	-0.31
Capex per share	-0.02	0	-0.02	-0.11	-0.02

Frequently Asked Questions

What is Cytosorbents Corporation stock symbol ?

Cytosorbents Corporation is a US stock , located in Monmouth junction of New jersey and trading under the symbol CTSO

What is Cytosorbents Corporation stock quote today ?

Cytosorbents Corporation stock price is $1.37 today.

Is Cytosorbents Corporation stock public?

Yes, Cytosorbents Corporation is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 170.88K
Market Capitalization 65.89M
Employee 221
CEO Dr. Phillip P. Chan
Headquarters Monmouth Junction,NEW JERSEY,US
IPO Date 2005-06-17
Website https://www.cytosorbents.com

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.